Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for BioScience Health Innovations (BHIC) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • BioScience Health Innovations' Cash & Equivalents rose 24194.32% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 24194.32%. This contributed to the annual value of $662517.0 for FY2024, which is 334379.35% up from last year.
  • As of Q3 2025, BioScience Health Innovations' Cash & Equivalents stood at $1.1 million, which was up 24194.32% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, BioScience Health Innovations' Cash & Equivalents ranged from a high of $1.3 million in Q2 2025 and a low of $374.0 during Q2 2021
  • Its 5-year average for Cash & Equivalents is $265360.9, with a median of $41988.0 in 2023.
  • In the last 5 years, BioScience Health Innovations' Cash & Equivalents crashed by 9836.5% in 2021 and then soared by 643903.74% in 2022.
  • Over the past 5 years, BioScience Health Innovations' Cash & Equivalents (Quarter) stood at $96134.0 in 2021, then crashed by 70.52% to $28343.0 in 2022, then plummeted by 32.12% to $19238.0 in 2023, then surged by 3343.79% to $662517.0 in 2024, then soared by 71.98% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.3 million for Q2 2025, and $1.0 million during Q1 2025.